Novartis targets undruggable cancers with $1.9bn Antares Therapeutics deal - Pharmaceutical Technology

Antares’ lead precision oncology programme is expected to enter the clinic in 2026. Antares’ lead precision oncology programme is expected to enter the clinic in 2026. Oncology sales for Novartis grew 18% to $16.8bn in 2025, cementing its status as the big pharma company’s largest therapeutic segment. Credit: Taljat David/Shutterstock.com. Just a year after spinning out from Scorpion Therapeutics, Antares Therapeutics has secured a big pharma partner to help advance its pipeline of undruggable oncology targeting therapies. Novartis has outlaid up to $1.9bn to collaborate with Antares Therapeutics, with the two companies working together to discover, develop, and commercialise small…

Source: Pharmaceutical Technology